Publications and Abstracts

June 2024

A Phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer

Poster Presentation

American Society of Clinical Oncology Annual Meeting (ASCO) 2024

June 2024

Antitumor activity of nab-sirolimus versus mTOR inhibitors temsirolimus, sirolimus, and everolimus in A549 NSCLC xenografts

Abstract

American Society of Clinical Oncology Annual Meeting (ASCO) 2024

April 2024

Evaluation of nab-sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines

Poster Presentation

American Association for Cancer Research (AACR) 2024 Annual Meeting

April 2024

Correlation of nab-sirolimus tumor drug levels and improved tumor suppression in KRAS G12C non-small cell lung cancer xenografts treated with nab-sirolimus in combination with KRAS inhibitors

Poster Presentation

American Association for Cancer Research (AACR) 2024 Annual Meeting

March 2024

Phase II Trial of nab-sirolimus in Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update

Publication

Journal of Clinical Oncology

March 2024

nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 in a Phase 2, Multicenter, Open-label Tumor-Agnostic Trial: PRECISION 1

Poster Presentation

Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer 2024

March 2024

nab-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer: A Phase 2, Open-Label, Single-Arm, Prospective, Multicenter Study

Poster Presentation

Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer 2024

March 2024

Response to Treatment with nab-Sirolimus in Patients with Perivascular Epithelioid Cell Sarcoma (PEComa) of Gynecologic or Peritoneal Origin: Subgroup Analysis from AMPECT

Oral Presentation

Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer 2024

March 2024

Analysis of inactivating TSC1 and TSC2 alterations in a real-world patient population with advanced gynecological cancers in the Foundation Medicine genomic database

Poster Presentation

Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer 2024

January 2024

Analysis of inactivating alterations in TSC1 and TSC2 in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database

Poster Presentation

ASCO Genitourinary Cancers Symposium

January 2024

PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2

Poster Presentation

ASCO Genitourinary Cancers Symposium

January 2024

Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas

Poster Presentation

ASCO Gastrointestinal Cancers Symposium

January 2024

Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in TSC1 and TSC2 using the Foundation Medicine genomic database

Poster Presentation

ASCO Gastrointestinal Cancers Symposium

January 2024

PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2

Poster Presentation

ASCO Gastrointestinal Cancers Symposium

November 2023

Phase 2, Multicenter, Global, Open-Label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 and TSC2 (PRECISION 1)

Poster Presentation

AACR Special Conference in Cancer Research

November 2023

Response to Treatment With nab-Sirolimus Among Patients With Malignant PEComa of Uterine Origin: A Subanalysis From AMPECT

Poster Presentation

AACR Special Conference in Cancer Research

November 2023

A Phase 2, Open-Label, Single-Arm, Prospective, Multi-Center Study of nab-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer

Poster Presentation

AACR Special Conference, Endometrial Cancer 2023

November 2023

Phase 2, Multicenter, Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 (PRECISION1)

Poster Presentation

CTOS 2023 Annual Meeting

October 2023

Inactivating TSC1 and TSC2 alterations, co-mutations, and genomic instability in advanced cancers: Analysis of a real-world (RW) patient population using the Foundation Medicine genomic database

Poster Presentation

EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium (ENA)

October 2023

Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 (PRECISION 1)

Poster Presentation

EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium (ENA)

October 2023

Real-world (RW) characterization and frequency of TSC1 and/or TSC2 alterations collected from tumor tissue and liquid biopsies from the Tempus genomic database in patients with advanced cancer

Poster Presentation

EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium (ENA)

October 2023

Evaluation of nab-Sirolimus in Combination With PI3K Pathway Inhibitors to Overcome PI3K/mTOR A117Resistance in PI3K-Mutant Breast Cancer Cell Lines

Poster Presentation

EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium (ENA)

October 2023

Phase 2 Study of nab-Sirolimus in Patients with Well-differentiated and Advanced or Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract, Lung, or Pancreas

Poster Presentation

North American Neuroendocrine Tumor Society (NANTS) 2023

October 2023

Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Inactivating Alterations in TSC1 or TSC2 (PRECISION I)

Poster Presentation

North American Neuroendocrine Tumor Society (NANTS) 2023

June 2023

Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes (PRECISION 1)

Poster Presentation

American Society of Clinical Oncology Annual Meeting (ASCO) 2023

April 2023

Biomarker Analysis From AMPECT Correlating Response to nab-Sirolimus in PEComa With TSC1 and TSC2 Inactivating Alterations

Poster Presentation

American Association for Cancer Research (AACR) 2023 Annual Meeting

April 2023

Synergistic Antitumor Activity of nab-Sirolimus in Combination With KRAS Inhibitors Sotorasib and Adagrasib in KRAS G12C Non-Small Cell Lung Cancer and Bladder Cancer Xenografts

Poster Presentation

American Association for Cancer Research (AACR) 2023 Annual Meeting

April 2023

Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 or TSC2 (PRECISION I)

Poster Presentation

American Association for Cancer Research (AACR) 2023 Annual Meeting

March 2023

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

Poster Presentation

Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer 2023

March 2023

Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT

Poster Presentation

Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer 2023

February 2023

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

Poster Presentation

American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2023

January 2023

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

Poster Presentation

American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2023

November 2022

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

Poster Presentation

Connective Tissue Oncology Society (CTOS) Annual Meeting 2022

November 2022

Management of adverse events in the AMPECT trial of nab-sirolimus for the treatment of advanced malignant perivascular epithelioid cell neoplasm (PEComa)

Poster Presentation

Connective Tissue Oncology Society (CTOS) Annual Meeting 2022

November 2022

Study-end analysis from AMPECT, an open-label, phase 2 registration trial of patients with advanced malignant PEComatreated with nab-sirolimus, showing durability of response and long-term safety

Poster Presentation

Connective Tissue Oncology Society (CTOS) Annual Meeting 2022

October 2022

KRAS G12C-Mutated NSCLC and Bladder Cancer Xenografts Treated With Sotorasib and Adagrasib in Combination With the mTOR Inhibitor nab-Sirolimus Show Improved Antitumor Activity

Poster Presentation

EORTC-NCI-AACR Symposium October 2022, Barcelona, Spain

October 2022

nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program

Poster Presentation

Academy of Managed Care Pharmacy (AMCP) Nexus 2022

September 2022

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

Poster Presentation

International Gynecologic Cancers Society (IGCS) 2022 Annual Global Meeting

June 2022

nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program

Poster Presentation

American Society of Clinical Oncology (ASCO) Annual Meeting 2022

November 2021

nab-Sirolimus in Patients with Malignant PEComa Previously Treated With mTOR Inhibitors: Emerging Experience From An Expanded Access Program

Oral Presentation

Connective Tissue Oncology Society (CTOS) Annual Meeting 2021

November 2021

Final Analysis from AMPECT, an Open-Label Phase 2 Registration Trial of nab-Sirolimus for Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)

Oral Presentation

Connective Tissue Oncology Society (CTOS) Annual Meeting 2021

October 2021

nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

Publication

Journal of Clinical Oncology

October 2021

nab-Sirolimus improves mTOR pathway suppression and antitumor activity versus oral mTOR inhibitors in PTEN null bladder cancer (UMUC3) and TSC2 null liver cancer (SNU398) xenografts

Poster Presentation

American Associate for Cancer Research (AACR)-NCI-EORTC Virtual International Conference

June 2021

Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations

Poster Presentation

American Society of Clinical Oncology (ASCO) Annual Meeting 2021

November 2020

Long-Term Follow-Up from AMPECT, an Open-Label Phase 2 Registration Trial of nab-Sirolimus for Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)

Poster Presentation

Connective Tissue Oncology Society (CTOS) Annual Meeting 2020

June 2020

Long-term follow-up for duration of response (DOR) after weekly nab-sirolimus (ABI-009) in patients with advanced malignant perivascular epitlhelioid cell tumors (PEComa): Results from a registrational open-label phase 2 trial, AMPECT

Oral Presentation

American Society of Clinical Oncology (ASCO) Annual Meeting 2020

June 2020

Phase I results from a phase 1/2 multi-center study of nab-sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss

Conference Presentation

American Society of Clinical Oncology (ASCO) Annual Meeting 2020

November 2019

A phase 2 trial with ABI-009 (nab-sirolimus) as single-agent and combinations in recurrent high-grade glioma (rHGG) and in newly diagnosed glioblastoma (ndGBM)

Poster Presentation

Society for NeuroOncology (SNO) Annual Meeting and Education Day 2019

November 2019

Mutational and Biomarker Correlative Analysis of mTOR Pathway Aberrations in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa) Treated With nab-Sirolimus: Results From AMPECT, an Open-Label Phase 2 Registration Trial

Poster Presentation

Connective Tissue Oncology Society (CTOS) Annual Meeting 2019

November 2019

Weekly nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Results From AMPECT, An Open-Label Phase 2 Registration Trial With Independent Radiology Review

Oral Presentation

Connective Tissue Oncology Society (CTOS) Annual Meeting 2019

June 2019

ABI-009 (nab-sirolimus) in Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Preliminary Efficacy, Safety, and Mutational Status from AMPECT, an Open-label Phase II Registration Trial

Oral Presentation

American Society of Clinical Oncology (ASCO) Annual Meeting 2019

May 2019

ABI-009, nab-Sirolimus, an mTOR Inhibitor with High Lung Accumulation in Preclinical Models: Initial Results from an Ongoing Phase I/II Safety and Preliminary Efficacy Study in Severe PAH

Poster Presentation

American Thoracic Society International Conference 2019

April 2019

Severe Pulmonary Arterial Hypertension Treated with ABI-009, nab-Sirolimus, an mTOR Inhibitor

Mini Oral Presentation

The International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting and Scientific Sessions

April 2019

Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (nab-Sirolimus)

Poster Presentation

American Association for Cancer Research (AACR) 2019 Annual Meeting

April 2019

ABI-009 (nab-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors

Poster Presentation

American Association for Cancer Research (AACR) 2019 Annual Meeting

March 2019

Patients With Severe Pulmonary Arterial Hypertension Treated With ABI-009, nab-Sirolimus, an mTOR Inhibitor: Interim Results From a Phase 1 Clinical Trial

Poster Presentation

American College of Cardiology (ACC) Annual Scientific Session & Expo 2019

January 2019

A phase I/II multicenter study of ABI-009 (nab-sirolimus) combined with FOLFOX and bevacizumab as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss

Poster Presentation

2019 ASCO Gastrointestinal Cancers Symposium

December 2018

Improved tumor penetration, anti-tumor activity, and survival of ABI-009 (nab-sirolimus) versus oral rapamycin and everolimus and investigation of mTOR pathway inhibition

Poster Presentation

American Association for Cancer Research (AACR) Special Conference on Targeting PI3K/mTOR Signaling 2018

June 2018

Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa)

Poster Presentation

American Society of Clinical Oncology (ASCO) Annual Meeting 2018

April 2018

Antitumor activity of ABI-009 (nab-rapamycin) in combination with anti-PD1 antibody in a syngeneic mouse model of B16 melanoma

Poster Presentation

American Association for Cancer Research (AACR) 2018 Annual Meeting